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Abstract
Background: Fusion transcripts are found in many tissues and have the potential to create novel functional
products. Here, we investigate the genomic sequences around fusion junctions to better understand the
transcriptional mechanisms mediating fusion transcription/splicing. We analyzed data from prostate (cancer)
cells as previous studies have shown extensively that these cells readily undergo fusion transcription.
Results: We used the FusionMap program to identify high-confidence fusion transcripts from RNAseq data.
The RNAseq datasets were from our (N = 8) and other (N = 14) clinical prostate tumors with adjacent non-cancer cells,
and from the LNCaP prostate cancer cell line that were mock-, androgen- (DHT), and anti-androgen- (bicalutamide,
enzalutamide) treated. In total, 185 fusion transcripts were identified from all RNAseq datasets. The majority (76 %) of
these fusion transcripts were ‘read-through chimeras’ derived from adjacent genes in the genome. Characterization of
sequences at fusion loci were carried out using a combination of the FusionMap program, custom Perl scripts, and the
RNAfold program. Our computational analysis indicated that most fusion junctions (76 %) use the consensus GT-AG
intron donor-acceptor splice site, and most fusion transcripts (85 %) maintained the open reading frame. We assessed
whether parental genes of fusion transcripts have the potential to form complementary base pairing between parental
genes which might bring them into physical proximity. Our computational analysis of sequences flanking fusion junctions
at parental loci indicate that these loci have a similar propensity as non-fusion loci to hybridize. The abundance
of repetitive sequences at fusion and non-fusion loci was also investigated given that SINE repeats are involved in
aberrant gene transcription. We found few instances of repetitive sequences at both fusion and non-fusion junctions.
Finally, RT-qPCR was performed on RNA from both clinical prostate tumors and adjacent non-cancer cells (N = 7), and
LNCaP cells treated as above to validate the expression of seven fusion transcripts and their respective parental genes.
We reveal that fusion transcript expression is similar to the expression of parental genes.
Conclusions: Fusion transcripts maintain the open reading frame, and likely use the same transcriptional machinery as
non-fusion transcripts as they share many genomic features at splice/fusion junctions.
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Background
The latest estimates indicate that the human genome
comprises only 20,687 protein coding genes [1]. This
number seems surprisingly low, considering the pheno-
typic complexity of humans. Adding another layer of
complexity, it is now appreciated that fusion transcripts
– which are derived of exons from two or more distinct
genes – can exponentially increase the protein coding/
functional capacity of the human genome [2]. There is
now a body of evidence to indicate that numerous genes
within the human genome are transcribed as fusion
transcripts [3–5]. Notably, some fusion transcripts are
more tissue specific than non-fusion transcripts, and are
translated into proteins [5].
Here, we use prostate (cancer) cells as a model to
study fusion transcription given extensive studies that
indicate that the prostate readily expresses fusion tran-
scripts. For example, the most studied fusion in prostate
cancer is formed between the TMPRSS2 and ERG genes,
resulting in ERG transcription being driven by the
androgen-responsive TMPRSS2 promoter [6–8]. This fu-
sion is observed in ~50 % of primary prostate tumors,
and ~41 % of lymph node metastatic tumors [8]. Hun-
dreds of novel fusion genes that are formed by chromo-
somal rearrangements have since been discovered in
prostate cancer genomes [9, 10]. Interestingly, some of
these chromosomal rearrangement fusion genes can pro-
duce fusion transcripts comprising exons from more
than two genes [11]. The Chinnaiyan laboratory ex-
tended their seminal TMPRSS2-ERG study by using
RNAseq to identify 11 other fusion transcripts that are
not produced by chromosomal alterations (hereafter
termed transcription-induced transcripts) [12, 13]. Later
studies using RNAseq estimated that there may be as
many as 339 transcription-mediated fusion transcripts
that are expressed in the prostate [14]. Importantly,
Maher and colleagues revealed that some transcription-
mediated fusion transcripts such as SLC45A3-ELK4 are
more highly expressed in metastatic prostate cancers
compared to benign cells [12]. Other studies [15, 16]
have since correlated SLC45A3-ELK4 expression with an
unfavorable prostate cancer prognosis, resulting in a
growing interest in fusion transcription in the prostate
cancer biomarker field [17, 18].
A recent study of 974 diverse cancer cases has identi-
fied 198 fusion transcripts, some of which comprise kin-
ase genes that have great potential to be targeted
therapeutically [9]. Additionally, a more recent extensive
study of 7256 RNAseq libraries discovered 8020
transcription-mediated fusion transcripts, many of which
are expressed in the prostate and/or associated with
various types of cancer [19]. Interestingly, fusion tran-
scripts have also been found to be formed between mito-
chondrial DNA with nuclear DNA, occurring at a
similar frequency as fusion transcripts that comprise
solely of nuclear DNA [20].
In this study we characterized the genomic sequences
flanking fusion transcripts to better understand the
mechanisms that mediate fusion transcription, using
prostate (cancer) as a model given the aforementioned
extensive studies in this tissue. Indeed, a study in pros-
tate (cancer) cells reveals that the CTCF transcription
factor mediates changes in chromosomal conformation
that results in the possible formation of at least 56 fu-
sion transcripts {Qin, 2015 #33}. Here, we reveal that the
sequences flanking fusion loci are similar to non-fusion
loci, indicating that the mechanisms adopted by fusion
transcription are likely to be similar to non-fusion tran-
scription and intron splicing.
Results and discussion
Identification of fusion transcripts in prostate cancer
A recent study indicates that the number of protein cod-
ing genes in the human genome is similar to lower ver-
tebrates [21]. Thus, there has been a growing interest in
fusion transcription as a mechanism to account for some
of the phenotypic complexities of humans [2]. Here, we
used the FusionMap program to first identify fusion
transcripts in prostate (cancer) RNA-seq data sets as this
program offers one of the best compromises between
sensitivity and false positives [22]. Predicted fusion tran-
scripts were then searched against the genome using the
BLAT function of the UCSC genome browser, and
manually inspected to filter out predicted fusion tran-
scripts that map to other regions of the genome (false
positives).
This resulted in the detection of a total of 185 high-
confidence fusion transcripts from Ren and colleagues
(14 patients) and our (eight patients) dataset of clinical
prostate cancers and their adjacent non-cancer prostate
cells, and from our dataset of cultured LNCaP cells
treated with androgens (DHT) and anti-androgens (bica-
lutamide and enzalutamide) (Additional file 1). The ma-
jority of these fusion transcripts (140/185, 76 %) are
derived from genes that are located next to each other
in the genome, otherwise referred to as “read-through
transcripts” [13], or transcription induced chimeras [23, 24]
(Additional file 1). This observation is supported by a re-
cent study in prostate cancer cells that indicates that a high
percentage of fusion transcripts involve neighbouring genes
{Qin, 2015 #33}. Of the other fusion transcripts, 15 (8 %)
are derived from genes that are located on different chro-
mosomes, and 30 (16 %) are derived from non-adjacent
genes that are on the same chromosome (Fig. 1a and
Additional file 1). Notably, a majority of fusion tran-
scripts were solely detected in either Ren and col-
leagues (74 fusions, 40 %) or the LNCaP (56 fusions,
30 %) datasets (Fig. 1b), and some fusion transcripts
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were exclusively detected in LNCaP cells that were
treated with either bicalutamide (28 fusions, 29 %),
enzalutamide (19 fusions, 19 %), or DHT (13 fusions,
13 %) (Fig. 1c). This highlights the importance of
using many different biological data sets to identify
fusion transcripts.
Most fusion transcripts are formed at annotated exon
junctions, use classical GT-AG intron donor-acceptor motifs,
and preserve the open reading frame
Previous studies have characterized fusion transcript
splice sites at the exon usage level [3] or at the RNA se-
quence level [4], but to our knowledge, there has been
no attempt to characterize the genomic sequence sur-
rounding fusion junctions. Thus, we have characterized
the nucleotide sequences flanking fusion junctions at the
genes that fusion transcripts are derived (hereafter re-
ferred to as parental genes) to better understand the
mechanisms that mediate fusion expression.
An analysis of fusion junctions revealed that most fu-
sion transcripts (160/185, 87 %) detected in our Fusion-
Map analysis are formed at the exon borders of either
one or both parental genes (Fig. 2a), and that most (140/
185, 76 %) use the canonical GT-AG intron donor-
acceptor splice sites (Fig. 2b). Interestingly, this observa-
tion also applied to fusion transcripts that are the result
of chromosomal rearrangements such as TMPRSS2-
ERG. Thus, fusion transcripts that are located within
genomic regions that undergo genomic rearrangements
still use the same transcriptional machinery as non-
fusion loci, unless chromosomal breakpoints occur
within exons. Notably, 50 % (12/24) and 70 % (46/66) of
fusion transcripts that use the classical GT-AG intron
donor-acceptor sites correspond to fusion junctions that
were located at neither or only one exon boundary of
the parental genes, respectively (Additional file 1). This
indicates that these fusion transcripts are not the result
of chromosomal breakpoints that occur within exons,
but rather use classical gene transcription mechanisms
to generate alternative exon boundaries. Importantly,
140 (85 %) of the fusion transcripts maintain the original
open reading frame of the parental genes (Fig. 2c), open-
ing the possibility that fusion transcripts can be trans-
lated into distinct functional proteins with unique
biological properties. Indeed, 12 fusion proteins have
already been detected in various human tissues [5].
Computational prediction indicates that fusion junctions
and non-fusion splice sites have similar propensities to
hybridize
It has been proposed that fusion transcripts might be
the result of ‘chromosomal looping’ that brings distal
loci together [25]. Thus, a computational analysis of the
sequences flanking fusion junctions of the parental gene
loci was performed to determine the capacity of these
two loci to hybridize (Fig. 3a and Additional file 2),
thereby bringing distal regions together to mediate one
continuous transcriptional event that produces a fusion
(See figure on previous page.)
Fig. 1 a Circos plot from RNAseq data of fusion transcripts from the Ren et. al. dataset [29], from our clinical prostate cancers and adjacent non-
cancer prostate cells (n = 8), and from LNCaP prostate cancer cells that were treated with either 10 nM androgen (DHT) or 10 μM anti-androgen
(bicalutamide and enzalutamide). b Venn diagram detailing how many unique fusion transcripts were detected between the different RNAseq
datasets. c Venn diagram detailing how many unique fusion transcripts were detected between androgen or anti-androgen treated LNCaP cells
Fig. 2 a Pie graph showing the proportion of fusion points that occur at the exon boundaries of one, both or neither genes that comprise the
fusion transcript. b Bubble plot of the number of fusion transcripts that use the AT-AC, CT-AC, CT-GC, GC-AG, and GT-AG donor-acceptor splice
sites. Bubble size represents the average gene expression (larger = greater expression) for fusion transcripts within that donor-acceptor class. c Pie
chart of the percentage of fusion transcripts that maintain the original reading frames of the genes that comprise the fusion transcripts (inner pie
chart). The outer pie chart represents the nucleotide position (0, 1, 2 = 1st, 2nd, and 3rd nucleotide, respectively) within the codon of the first (number before
arrow) and second (number after arrow) genes at the fusion points of those respective genes
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transcript. Our hypothesis stems from the RNA splicing
process which similarly involves a series of steps com-
prising multiple nucleotide hybridizations between
snRNA/ribonucleoprotein complexes with the target
pre-mRNA [26]. We found no obvious difference in both
the regions of hybridization, and the total number of hy-
bridized sequences between parental gene loci of fusion
transcripts (Fig. 3b, red lines) compared to canonical
exon-exon boundaries of genes from the NCBI RefSeq
database (Fig. 3b, blue lines). MEME analysis was also
undertaken to assess for motifs that might promote
genomic hybridization between parental gene loci. The
predicted hybridized nucleotides of two gene 1/gene 2
combinations have different motifs between fusion and
non-fusion loci (Fig. 3b, top panel, and third panel from
top), while predicted hybridized nucleotides between
gene 1 upstream and gene 2 upstream had G- and A-
rich motifs (Fig. 3b, second panel from top). Notably,
predicted hybridized nucleotides between gene 1 down-
stream and gene 2 upstream had similar G-rich motifs
in both fusion and non-fusion loci (Fig. 3b, bottom
panel).
(See figure on previous page.)
Fig. 3 a Diagram showing 100 nt of genomic sequence upstream (solid line under gene) and downstream (dotted line under gene) of the point
of fusion at the two genes comprising the fusion transcript that were used for hybridisation analysis. b The line graph represents the number of
fusion transcripts that have complementary nucleotides (y-axis) at the respective distance (x-axis) from the point of fusion (x-axis = 0) between the
up- and downstream sequences from gene 1 and gene 2. The histogram represents the average number of complementary nucleotides between
the up- and down-stream sequences from gene 1 and gene 2. The MEME result (coloured ACGT nucleotides) represents motifs of complementary
sequences between the up- and down-stream sequences from gene 1 and gene 2. Up- and down-stream sequences from random non fusion intron
splice sites were used for comparison
Fig. 4 a Diagram showing 100 nt of genomic sequence upstream (solid line under gene) and downstream (dotted line under gene) of the point
of fusion at the two genes comprising the fusion transcript that were used to identify repetitive sequences. b Repeats from six families (DNA, LINE,
Low complexity, LTR, Simple repeat, SINE) were detected at fusion (red regions) and non-fusion (random, blue regions) regions at both gene loci
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Fusion loci are depleted of repetitive sequences
We also assessed whether there was a selection of re-
petitive sequences at fusion loci as it has been found that
Alu repeats mediate aberrant gene transcription through
exonization [27]. Sequence analyses of genomic se-
quences flanking the fusion junctions (red blocks) at
parental gene loci (Fig. 4a) indicate that they have a low
abundance of repetitive sequences. For example, only six
repeat families were found within these regions (DNA,
LINE, low complexity, LTR, simple repeat, SINE)
(Fig. 4b). The highest prevalence of repeats corresponds
to SINEs that were predominantly located further away
from the point of fusion, but these account for only
6.5 % (11/168) of all fusions (Fig. 4b and Additional file
3). Apart from LTRs at the gene 1 parental loci, the
number of repetitive sequences at non-fusion loci (blue
blocks) was generally similar to parental gene loci of fu-
sion transcripts (Fig. 4b). Given the likely use of similar
transcriptional mechanisms between fusion and non-
fusion loci from aforementioned observations, the lack
of repetitive sequences at fusion loci is not surprising as
exonic and splice regions are generally well conserved
[28] to ensure functionality of important genes.
Fusion transcripts are regulated by androgen and/or
therapeutic anti-androgens
We assessed whether fusion transcript expression corre-
lates with the parental gene expression in order to better
understand the coordination of fusion expression with
their parental genes. Thus, an RT-qPCR analysis was
undertaken on six fusion transcripts that were in frame,
and from frameshift classes with the most fusion tran-
scripts. These include CTBS-GNG5 (2→0), DHRS1-
RABGGTA (0→), SIDT2-TAGLN (2→), HARS2-ZMAT2
(→0), NOS1AP-C1orf226 (0→1), and C17orf106-CDK3
(→). Three of these fusion transcripts comprise of genes
that are adjacent to each other in the genome (HARS2-
ZMAT2, DHRS1-RABGGTA, SIDT2-TAGLN), with the
other three derived from non-adjacent genes (NOS1AP-
C1orf226, C17orf106-CDK3, CTBS-GNG5). RT-qPCR
was also carried out on the C1QTNF3-AMACR (1→1)
as a representative transcript with an interrupted reading
frame. Our analysis indicates that all candidate fusion
transcripts are either two-fold higher- (DHRS1-
RABGGTA, CTBS-GNG5, C17orf106-CDK3, SIDT2-
TAGLN) or lower- (NOS1AP-c10rf226, HARS-ZMAT2,
C1QTNF3-AMACR) expressed after androgen or anti-
Table 1 Summary of fusion expression by RT-qPCR
(anti)-androgen regulationa Tumor expressiona
Fusion transcript Gene DHT BIC ENZ T/N
NOS1AP-c1orf226 Fusion ↓ ↓ ↓ -
NOS1AP ↓ ↓ ↓ -
c1orf226 ↓ ↓ ↓ -
HARS-ZMAT2 Fusion ↓ - - -
HARS ↓ ↓ ↑ -
ZMAT2 ↓ ↓ - ↓
DHRS1-RABGGTA Fusion ↑ ↓ - ↓
DHRS1 - - - -
RABGGTA - - - -
CTBS-GNG5 Fusion ↑ ↑ ↑ NE
CTBS ↑ ↑ ↑ -
GNG5 - - - -
C17orf106-CDK3 Fusion ↑ ↑ - NE
C17orf106 ↑ ↑ ↑ NE
CDK3 ↑ ↑ - -
SIDT2-TAGLN Fusion ↑ ↑ ↑ NE
SIDT2 ↑ ↑ ↑ ↓
TAGLN ↑ ↑ ↑ ↓
C1QTNF3-AMACR Fusion ↓ ↓ ↓ -
C1QTNF3 ↓ - - -
AMACR ↑ - - ↑
aAt least two-fold higher- (↑), lower- (↓), or no change (-) in expression after (anti)-androgen treatment to mock treatments
bAt least four of seven tumours with at least 2-fold over- (↑), under- (↓), or no change (-) in expression in tumors relative to non-tumor cells
DHT dihydrotestosterone (androgen), BIC bicalutamide (anti-androgen), ENZ enzalutamide (anti-androgen), NE not expressed
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androgen treatment in LNCaP cells (Table 1 and
Additional file 4). In many cases, the androgen and
anti-androgen regulation of at least one of the paren-
tal genes is similar to the fusion transcript (Table 1
and Additional file 4). C1QTNF3-AMACR was the
notable exception (Table 1 and Additional file 4). The
similarity in expression between fusion transcripts
and their parental genes is not surprising considering
that the splice site usage at fusion junctions is similar
to those of non-fusion transcripts. Interestingly, all
seven candidate fusion transcripts were regulated by
androgen (DHT) and/or therapeutic anti-androgens
(bicalutamide, enzalutamide), indicating that they
might be important in disease progression and/or
treatment resistance.
Some fusion transcripts are differentially expressed in
prostate tumors
Of the seven candidate fusion transcripts, only four
(NOS1AP-c10rf226, HARS-ZMAT2, DHRS1-RABGGTA,
C1QTNF3-AMACR) could be readily detected in clinical
prostate tumors and/or adjacent non-cancer cells
(Table 1 and Additional file 5). Of these, C1QTNF3-
AMACR has an expression profile that is distinct from
both parental genes (Table 1 and Additional file 5).
Interestingly, the DHRS1-RABGGTA fusion transcript is
less expressed in tumors compared to adjacent non-
cancer cells (Table 1 and Additional file 5). Furthermore,
five of the fusion transcripts detected in this study
(NOS1AP-c10rf226, HARS-ZMAT2, DHRS1-RABGGTA,
CTBS-GNG5, and SIDT2-TAGLN) were found in both
our clinical RNAseq dataset comprised of Caucasian
men, and in Ren and colleagues dataset which com-
prised of Han Chinese men [29]. Thus, these fusion
transcripts are great candidates for further studies as
they are readily expressed in different ethnicities.
Fusion loci undergo extensive alternative transcription
Finally, we assessed for variant fusion transcripts given
that most loci undergo variant transcription [19]. A re-
cent large-scale RNAseq study comprising 7256 libraries
from multiple cancers [19] was interrogated, revealing
that 61 transcripts harbored the same exon junctions as
the transcripts detected in our prostate (cancer) data set
(Additional file 6). These 61 transcripts accounted for
only 17 of the 185 fusion transcripts detected in this
study (Additional file 6). This indicates that multiple
variant fusion transcripts use the same exon junctions.
In agreement, in addition to the 17 transcription-
mediated fusion transcripts of our prostate-derived data-
set, the Iyer et al. [19] dataset revealed that parental loci
were extensively spliced, with 124/168 presenting alter-
native fusion transcripts (Additional file 1). We thus
propose that these loci are highly amendable to fusion
and alternative transcription. An example of extensive
fusion transcription from the Iyer et al. dataset for the
seven candidate fusion loci from this study is shown in
Fig. 5.
Conclusions
Using a conservative filtering process, we have identified
185 high confidence fusion transcripts that are readily
expressed in prostate (cancer) cells in order to accurately
analyze the sequences around fusion junctions in order
to better understand fusion transcription and/or splicing.
We reveal that fusion splices sites generally use the same
nucleotide sequences as non-fusion transcripts, thereby
indicating that fusion transcription likely co-opts the
same transcriptional processes. However, this hypothesis
may only apply to “read-through” chimeras which com-
prise the majority (76 %) of fusions that were detected in
this study. Regardless of the mechanism, the recombin-
ation of exons from biologically distinct genes provides
an interesting source of genetic variation that warrants
further study which will further our understanding of
the transcriptional nuances of more evolutionary com-
plex species such as humans.
Methods
Ethical approval and consent to publish
All men have given written informed consent to the
Australian Prostate Cancer BioResource to use their tis-
sue and associated medical records for this study, as well
as for publication of de-identified patient data. This
study is also approved by the Queensland University of
Technology Ethics committee (1000001165).
Clinical prostate cancers
FFPE blocks from prostate tumors and their adjacent
non-cancer cells were obtained from the Australian
Prostate Cancer Bio-Resource tumor bank. Cells were
extracted from formalin-fixed and paraffin-embedded
sections of micro-dissected benign and malignant pros-
tate tissues. Tissue blocks containing the tumor cells
were serially sectioned (20 μm sections), transferred to
glass slides, stained with methyl green, and tumor areas
were marked and Gleason grades scored by a pathologist
(Additional file 7). Marked areas were manually macro-
dissected under a microscope using a sterile injection
needle (size 0.65 × 25 mm). RNA was extracted using the
miRNeasy FFPE kit (QIAGEN, Chadstone, Australia).
RNA sequencing
RNA from eight clinical prostate tumors and adjacent
non-cancer cells was sequenced by the Australian Gen-
ome Research Facility (http://www.agrf.org.au/). Briefly,
ribosome-depleted RNA was paired-end sequenced on
the Illumina HiSeq 2500 platform using 100 nt read
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Fig. 5 Diagram of other fusion transcripts expressed at the seven candidate fusion loci. Red UCSC Bed tracks indicate fusion transcripts discovered by
Iyer et al. [19]. Parental genes that fusion transcripts were derived in our study are represented as green tracks, and other genes located at that locus
are represented as blue tracks. The fusion junctions discovered in this study is also shown
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lengths, and using the Illumina TruSeq strand-specific
protocol (Life Technologies, Mulgrave, Australia). On
average, 23.3 million reads were sequenced from each
sample (Additional file 7).
Detection of fusion transcripts
Fusion transcripts were identified using the FusionMap
program [30] on the following RNAseq datasets: LNCaP
prostate cancer cells treated with androgen (DHT) and
therapeutic anti-androgens (bicalutamide, enzalutamide)
[31], 14 clinical prostate cancers and their adjacent non-
cancer cells [29], and from our RNAseq dataset of eight
clinical prostate tumors and their adjacent non-cancer
cells. FusionMap analysis was performed with raw RNA-
seq data files (FASTQ format), the Human. B37 reference
genome and annotations, and default FusionMap parame-
ters except for the following: PairedEnd = True, RnaMode
= True, MinimalFusionAlignmentLength = 30, FusionRe-
portCutoff = 1, NonCanonicalSpliceJunctionPenalty = 4. All
predicted fusions were manually screened against the gen-
ome using the 30 nt fusion junction sequence from the
FusionMap result and the UCSC genome browser BLAT
tool [32]. Fusions mapping to several locations in the
genome were discarded. The ‘SplicePatternClass’, ‘Frame-
ShiftClass’, and ‘OnExonBoundary’ output fields from
FusionMap were used to characterize the sequences at fu-
sion loci.
Custom Perl scripts matching exon-exon junction co-
ordinates from assembled bed and GTF files from a recent
large-scale RNAseq study [19] against fusion junctions
(gene 1 and gene 2 junction co-ordinates) from this study
was used to identify common fusions between this study
and from the Yu et. al study. Variant fusion transcripts at
the 185 fusion loci from this study were detected by man-
ual inspection using Yu and colleagues UCSC MiTran-
scriptome browser (http://mitranscriptome.org/).
In silico base pair hybridization analysis of sequences
flanking fusion splice sites
The computational workflow for analyzing hybridization
of gene 1 and gene 2 genomic sequences is detailed in
Additional file 2A. Briefly, 100 nt of genomic sequence
up- and down-stream of fusion splice sites at genes com-
posing the fusion transcript were obtained using a custom
Perl script and RefSeq sequences. The up- or down-
stream sequences of gene 1 were concatenated to the up-
or down-stream sequences of gene 2 using a spacer of 20
‘N’ nucleotides. The four combinations of sequences sub-
jected to complementary sequence analysis are as follows:
upstream gene 1–N20–upstream gene 2, upstream gene
1–N20–downstream gene 2, downstream gene 1-N20–up-
stream gene 2, downstream gene 1–N20– downstream
gene 2 (Additional file 2B). The DNA strand used for the
sequences corresponds to the ‘strand’ output field from
FusionMap. These four sequences were then analyzed for
sequence hybridization using RNAfold which can use
single-stranded DNA inputs [33]. A custom Perl script
was then used to filter for nucleotides that hybridized be-
tween gene 1 and gene 2 sequences, as opposed to nucleo-
tides that hybridized within gene 1 or gene 2 sequences
(Additional file 2C). These hybridized sequences between
gene 1 and gene 2 were then concatenated, and sequences
comprising at least eight nucleotides were subjected to
MEME analysis [34] to identify motifs. As a control, 185
non-fusion sequences from random consecutive exon
splice sites of random genes (RefSeq genes) were used.
In silico analysis for repetitive sequences at fusion loci
The 100 nucleotide sequences both up- and down-
stream of fusion loci from above was also subjected
to in silico analysis for the presence of repetitive
DNA sequences which might mediate fusion tran-
scription. However, for simplicity, only fusion tran-
scripts from the same chromosome and which are
not sense-antisense fusions (168 fusion transcripts)
were chosen for analysis. A subset (168 of 185) of the
100 nucleotide sequences flanking random exons of
random genes from above were also assessed to de-
termine the baseline distribution of repetitive se-
quences at non-fusion loci. Repetitive sequences were
defined by the RepeatMasker library (hg19.fa.out, Re-
peat Library 20120124, http://www.repeatmasker.org/).
The prevalence of repetitive DNA near fusion and
non-fusion splice sites where determined if the start
and end coordinates of repetitive DNA overlapped
with the start and end coordinates of the 100 nucleo-
tide flanking sequences.
Cell culture and RT-qPCR
The androgen receptor positive, LNCaP prostate can-
cer cell line was treated with androgen (10 nM DHT)
(Sigma-Aldrich, Sydney, Australia), or therapeutic
anti-androgens (10 μM bicalutamide, 10 μM enzaluta-
mide) (Selleck Chemicals, Waterloo, Australia) for
48 h as described previously [31]. RNA was extracted
from cells using Tri-reagent (Life Technologies), and
reverse transcribed (RT) using Superscript III (Life
Technologies) as described [35]. Quantitative PCR
(qPCR) was carried out using SYBR Green master-
mix (Life Technologies) using primers detailed in
Additional file 8. Fusion expression was determined
using the delta-delta CT method and using 18S as
the house-keeping gene. Data is represented as the
mean plus standard error from three independent
RNA. A student’s t-test was used to test for signifi-
cant differences in expression between mock and
(anti)-androgen treated cells. RT-qPCR was also
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carried out as above on cDNA generated from seven
tumor samples and adjacent non-cancer prostate cells.
Additional files
Additional file 1: Summary of genomic features at fusion loci.
(XLSX 76 kb)
Additional file 2: (A) Workflow of fusion analysis. (B) Strategy for
identifying nucleotide hybridisation between gene 1 and gene 2 at fusion
splice sites. (C) Strategy to determine whether hybridization results from
RNAfold are from within gene 1 and gene 2 sequences, or between them.
Left “(“and right”)” brackets represent hybridised sequences. Innermost
brackets are first matched (1, 2, 3, 4) to filter out hybridizations within
sequences. Outermost brackets (5, 6, 7, 8) are then matched to identify
hybridizations between sequences. N20 = linker spacer sequence.
(JPG 1688 kb)
Additional file 3: Repetitive sequences at fusion loci. (XLSX 87 kb)
Additional file 4: RT-qPCR analysis of (anti)-androgen regulation of
seven candidate fusions (NOS1AP-C1orf226, HARS2-ZMAT2, DHRS1-
RABGGTA, CTBS-GNG5, C17orf106-CDK3, SIDT2-TAGLN, C1QTNF3-
AMACR) in LNCaP prostate cancer cells. LNCaP cells were treated with
either ethanol (Mock), 10 μM anti-androgens (bicalutamide (BIC), enzalutamide
(ENZ)), or 10 nM androgen (DHT) for 24 h. Data is represented as the
SEM from 2–3 independent RNA. Top panel = fusion transcripts, middle and
bottom panels = parental genes that fusions were derived. (JPG 1528 kb)
Additional file 5: RT-qPCR analysis of differential expression of the
seven candidate fusions between tumours and adjacent non-cancer
prostate cells in a cohort (n= 7) of clinical prostate samples. Histograms
above 1, or below −1 represent a two-fold over- or under-expression in
tumors compared to adjacent non-cancer cells, respectively. Top panel =
fusion transcripts, middle and bottom panels = parental genes that fusions
were derived. (JPG 1877 kb)
Additional file 6: Fusion transcripts common to both Yu et al. dataset
and from this study. (XLSX 21 kb)
Additional file 7: Patient data. (XLSX 10 kb)
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